個(gè)人簡(jiǎn)介：

Dr. An is the founder of Curegenix. He is an expert in WNT signaling research with more than 20 years of drug discovery experiences in pharmaceutical industry. Prior to founding Curegenix, he was a Principlal Scientist / Project Leader at Amgen and a program director at Tularik in the US. He obtained an MD degree from Peking University Medical School and a PhD degree in Molecular Biology / Biochemistry from the University of Missouri-Columbia. After postdoctoral training in immunology at the University of California, San Francisco (UCSF), Dr. An became an assistant professor in the Department of Medicine at UCSF.

公司簡(jiǎn)介：

應(yīng)用國(guó)際先進(jìn)技術(shù)，研發(fā)全球首創(chuàng)First-in-class抗腫瘤、抗纖維化新藥 。廣州開(kāi)發(fā)區(qū)科技領(lǐng)軍人才，廣州市創(chuàng)業(yè)領(lǐng)軍人才，國(guó)家十二五重大新藥創(chuàng)制專(zhuān)項(xiàng)，著名風(fēng)險(xiǎn)投資機(jī)構(gòu)及跨國(guó)藥廠支持 。磷酸源生萘啶CGX1321完成中美雙報(bào)，開(kāi)展國(guó)際多中心臨床試驗(yàn)，在全球十多家頂級(jí)臨床中心完成臨床2a期試驗(yàn)（Harvard, Johns Hopkins, Duke, 北京腫瘤醫(yī)院等) 。臨床試驗(yàn)結(jié)果在美國(guó)臨床腫瘤學(xué)會(huì) (ASCO) 2023年會(huì)上應(yīng)邀做口頭報(bào)告 。自主研發(fā)項(xiàng)目聚焦WNT通路抑制劑，不涉獵其它靶點(diǎn)。將借助研發(fā)平臺(tái)和豐富經(jīng)驗(yàn)，為業(yè)內(nèi)同仁提供臨床前研究服務(wù)、中美臨床試驗(yàn)咨詢(xún)。